Home   Share this page on Facebook

Eric Lamaze (CAN) and Hickstead at the 2008 Olympic Games

The stallion Hickstead, winner of Individual Gold and Team Silver Medals at the 2008 Olympic Games under Canada's Eric Lamaze, has been approved for breeding based on performance by the Canadian Warmblood Horse Breeders Association, the American Holsteiner Horse Association (AHHA), and the KWPN of North America breed associations.

In addition to his performance at the 2008 Olympic Games, Hickstead's long list of accomplishments include winning the richest event in show jumping, the $1 million CN International at the 2007 Spruce Meadows "Masters" Tournament, and Team Silver and Individual Bronze Medals at the 2007 Pan American Games. Most recently, Hickstead won the $100,000 CN World Cup Grand Prix in Toronto in November followed by the €175,000 Rolex World Cup Grand Prix in Geneva in December. Based on these outstanding accomplishments, all three North American breed associations have all accepted Hickstead as an approved stallion.

"The CWHBA always puts performance first," said Chris Gould, Chairman of the Canadian Warmblood Horse Breeders Association. "We are pleased to have Hickstead in our stallion book. We hope he will become a super star sire, passing on his super star performance."

Hickstead is a 1996 brown Dutch Warmblood stallion standing 16hh. Sired by Hamlet, his dam is Jomara by the well-known and recently deceased stallion, Ekstein. Hickstead's bloodlines also feature such prominent show jumping names as Nimmerdor, Notaris, Ulft, Le Mexico and Joost. Based on his performance record, Hickstead is currently ranked the number one show jumping horse in the world by the World Breeding Federation of Sport Horses (WBFSH). He was also named 'Stallion of the Year' for 2008 by the KWPN.

Offered for the first time in North America for the 2009 season, Hickstead is represented by experienced horseman and breeder, Francis Berger. Due to Hickstead's competitive schedule, limited doses of frozen semen are available on a first-come, first-serve basis at a cost of $5,500 US per dose.